{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:44:08Z","timestamp":1790516648735,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4-6","license":[{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T00:00:00Z","timestamp":1659139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Up to 3.8% of human T-lymphotropic virus type-1 (HTLV-1)-infected asymptomatic carriers (AC) eventually develop HTLV-1-associated myelopathy (HAM). HAM occurs in patients with high (&gt;\u20091%) HTLV proviral load (PVL). However, this cut-off includes more than 50% of ACs and therefore the risk needs to be refined. As HAM is additionally characterised by an inflammatory response to HTLV-1, markers of T cell activation (TCA), \u03b2<jats:sub>2<\/jats:sub>-microglobulin (\u03b2<jats:sub>2<\/jats:sub>M) and neuronal damage were accessed for the identification of ACs at high risk of HAM. Retrospective analysis of cross-sectional and longitudinal routine clinical data examining differences in TCA (CD4\/CD25, CD4\/HLA-DR, CD8\/CD25 &amp; CD8\/HLA-DR), \u03b2<jats:sub>2<\/jats:sub>M and neurofilament light (NfL) in plasma in ACs with high or low PVL and patients with HAM. Comparison between 74 low PVL ACs, 84 high PVL ACs and 58 patients with HAM revealed a significant, stepwise, increase in TCA and \u03b2<jats:sub>2<\/jats:sub>M. Construction of receiver operating characteristic (ROC) curves for each of these blood tests generated a profile that correctly identifies 88% of patients with HAM along with 6% of ACs. The 10 ACs with this \u2018HAM-like\u2019 profile had increased levels of NfL in plasma and two developed myelopathy during follow-up, compared to none of the 148 without this viral-immune-phenotype. A viral-immuno-phenotype resembling that seen in patients with HAM identifies asymptomatic carriers who are at increased risk of developing HAM and have markers of subclinical neuronal damage.\n<\/jats:p>","DOI":"10.1007\/s13365-022-01088-x","type":"journal-article","created":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T19:02:53Z","timestamp":1659207773000},"page":"473-482","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Refining the risk of HTLV-1-associated myelopathy in people living with HTLV-1: identification of a HAM-like phenotype in a proportion of asymptomatic carriers"],"prefix":"10.1007","volume":"28","author":[{"given":"Daniel","family":"Harding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Rosadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Maria","family":"Tsoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3773-2390","authenticated-orcid":false,"given":"Graham P.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Dhasmana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,30]]},"reference":[{"key":"1088_CR1","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1046\/j.1365-3083.2002.01087.x","volume":"55","author":"GEA Brito-Melo","year":"2002","unstructured":"Brito-Melo GEA, Martins-Filho OA, Carneiro-Proietti ABF et al (2002) Phenotypic study of peripheral blood leucocytes in HTLV-I-infected individuals from Minas Gerais Brazil. Scand J Immunol 55:621\u2013628. https:\/\/doi.org\/10.1046\/j.1365-3083.2002.01087.x","journal-title":"Scand J Immunol"},{"key":"1088_CR2","doi-asserted-by":"publisher","unstructured":"Brito S, Furtado S, Andrade RG et al (2012) Monitoring the HTLV-1 proviral load in the peripheral blood of asymptomatic carriers and patients with HTLV-associated myelopathy\/tropical spastic paraparesis from a Brazilian cohort\u202f: ROC curve analysis to establish the threshold for risk disease. 671:664\u201371. https:\/\/doi.org\/10.1002\/jmv","DOI":"10.1002\/jmv"},{"key":"1088_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1590\/S0036-46652007000400007","volume":"49","author":"J Casseb","year":"2007","unstructured":"Casseb J, Posada-Vergara MP, Montanheiro P et al (2007) T CD4+ cells count among patients co-infected with human immunodeficiency virus type 1 (HIV-1) and human T-cell leukemia virus type 1 (HTLV-1): high prevalence of Tropical Spastic Paraparesis\/HTLV-1-Associated Myelopathy (TSP\/HAM). Rev Inst Med Trop Sao Paulo 49:231\u2013233","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"1088_CR4","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1186\/1471-2334-14-453","volume":"14","author":"R Coutinho","year":"2014","unstructured":"Coutinho R, Grassi MFR, Korngold AB et al (2014) Human T lymphotropic virus type 1 (HTLV-1) proviral load induces activation of T-lymphocytes in asymptomatic carriers. BMC Infect Dis 14:453. https:\/\/doi.org\/10.1186\/1471-2334-14-453","journal-title":"BMC Infect Dis"},{"key":"1088_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1089\/aid.2012.0132","volume":"28","author":"MA Demontis","year":"2012","unstructured":"Demontis MA, Hilburn S, Taylor GP (2012) Human T cell lymphotropic virus type 1 viral load variability and long-term trends in asymptomatic carriers and in patients with human T cell lymphotropic virus type 1-related diseases. AIDS Res Hum Retroviruses 28:28\u201330. https:\/\/doi.org\/10.1089\/aid.2012.0132","journal-title":"AIDS Res Hum Retroviruses"},{"key":"1088_CR6","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/cid\/cir766","volume":"54","author":"L Einsiedel","year":"2012","unstructured":"Einsiedel L, Fernandes L, Spelman T et al (2012) Bronchiectasis is associated with human T-lymphotropic virus 1 infection in an Indigenous Australian population. Clin Infect Dis 54:43\u201350. https:\/\/doi.org\/10.1093\/cid\/cir766","journal-title":"Clin Infect Dis"},{"key":"1088_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s0140-6736(85)92734-5","volume":"2","author":"A Gessain","year":"1985","unstructured":"Gessain A, Barin F, Vernant JC et al (1985) Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet (london, England) 2:407\u2013410. https:\/\/doi.org\/10.1016\/s0140-6736(85)92734-5","journal-title":"Lancet (london, England)"},{"key":"1088_CR8","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","volume":"3","author":"A Gessain","year":"2012","unstructured":"Gessain A, Cassar O (2012) Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol 3:388. https:\/\/doi.org\/10.3389\/fmicb.2012.00388","journal-title":"Front Microbiol"},{"key":"1088_CR9","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2174\/187152808785107642","volume":"7","author":"DU Gon\u00e7alves","year":"2008","unstructured":"Gon\u00e7alves DU, Proietti FA, Barbosa-Stancioli EF et al (2008) HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) inflammatory network. Inflamm Allergy Drug Targets 7:98\u2013107. https:\/\/doi.org\/10.2174\/187152808785107642","journal-title":"Inflamm Allergy Drug Targets"},{"key":"1088_CR10","doi-asserted-by":"publisher","unstructured":"Grassi MFR, Olavarria VN, Kruschewsky RA et al (2011) Human T cell lymphotropic virus type 1 (HTLV-1) proviral load of HTLV-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients according to new diagnostic criteria of HAM\/TSP. 1274:1269\u201374. https:\/\/doi.org\/10.1002\/jmv","DOI":"10.1002\/jmv"},{"key":"1088_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006967","volume":"13","author":"ME Haziot","year":"2019","unstructured":"Haziot ME, Gascon MR, Assone T et al (2019) Detection of clinical and neurological signs in apparently asymptomatic HTLV-1 infected carriers: association with high proviral load. PLoS Negl Trop Dis 13:e0006967. https:\/\/doi.org\/10.1371\/journal.pntd.0006967","journal-title":"PLoS Negl Trop Dis"},{"key":"1088_CR12","doi-asserted-by":"publisher","first-page":"6476","DOI":"10.1073\/pnas.78.10.6476","volume":"78","author":"Y Hinuma","year":"1981","unstructured":"Hinuma Y, Nagata K, Hanaoka M et al (1981) Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci USA 78:6476\u20136480. https:\/\/doi.org\/10.1073\/pnas.78.10.6476","journal-title":"Proc Natl Acad Sci USA"},{"key":"1088_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.1600-0404.1997.tb08156.x","volume":"169","author":"P H\u00f6llsberg","year":"1997","unstructured":"H\u00f6llsberg P (1997) Pathogenesis of chronic progressive myelopathy associated with human T-cell lymphotropic virus type I. Acta Neurol Scand Suppl 169:86\u201393. https:\/\/doi.org\/10.1111\/j.1600-0404.1997.tb08156.x","journal-title":"Acta Neurol Scand Suppl"},{"key":"1088_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0165-5728(89)90143-4","volume":"25","author":"S Ijichi","year":"1989","unstructured":"Ijichi S, Eiraku N, Osame M et al (1989) Activated T lymphocytes in cerebrospinal fluid of patients with HTLV-I-associated myelopathy (HAM\/TSP). J Neuroimmunol 25:251\u2013254. https:\/\/doi.org\/10.1016\/0165-5728(89)90143-4","journal-title":"J Neuroimmunol"},{"key":"1088_CR15","first-page":"1096","volume":"3","author":"JE Kaplan","year":"1990","unstructured":"Kaplan JE, Osame M, Kubota H, Igata A, Nishitani H, Maeda Y, Khabbaz RFJR (1990) The risk of development of HTLV-I-associated myelopathy\/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 3:1096\u20131101","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1088_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/jmv.1890380212","volume":"38","author":"H Kawai","year":"1992","unstructured":"Kawai H, Inui T, Kashiwagi S et al (1992) HTLV-I infection in patients with autoimmune thyroiditis (Hashimoto\u2019s thyroiditis). J Med Virol 38:138\u2013141. https:\/\/doi.org\/10.1002\/jmv.1890380212","journal-title":"J Med Virol"},{"key":"1088_CR17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1742-4690-8-81","volume":"8","author":"PDW Kirk","year":"2011","unstructured":"Kirk PDW, Witkover A, Courtney A et al (2011) Plasma proteome analysis in HTLV-1-associated myelopathy\/tropical spastic paraparesis. Retrovirology 8:81. https:\/\/doi.org\/10.1186\/1742-4690-8-81","journal-title":"Retrovirology"},{"key":"1088_CR18","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1086\/508899","volume":"194","author":"N Kwaan","year":"2006","unstructured":"Kwaan N, Lee T-H, Chafets DM et al (2006) Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. J Infect Dis 194:1557\u20131564. https:\/\/doi.org\/10.1086\/508899","journal-title":"J Infect Dis"},{"key":"1088_CR19","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/0140-6736(90)92896-p","volume":"336","author":"L LaGrenade","year":"1990","unstructured":"LaGrenade L, Hanchard B, Fletcher V et al (1990) Infective dermatitis of Jamaican children: a marker for HTLV-I infection. Lancet (london, England) 336:1345\u20131347. https:\/\/doi.org\/10.1016\/0140-6736(90)92896-p","journal-title":"Lancet (london, England)"},{"key":"1088_CR20","doi-asserted-by":"crossref","unstructured":"Maloney E, Cleghorn F, Morgan O et al (1998) Incidence of HTLV-I-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) in Jamaica and Trinidad. J Acquir Immune Defic Syndr Hum Retrovirol 17:167\u201370.\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9473019","DOI":"10.1097\/00042560-199802010-00011"},{"key":"1088_CR21","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/0140-6736(92)90699-4","volume":"339","author":"M Mochizuki","year":"1992","unstructured":"Mochizuki M, Yamaguchi K, Takatsuki K et al (1992) HTLV-I and uveitis. Lancet (london, England) 339:1110. https:\/\/doi.org\/10.1016\/0140-6736(92)90699-4","journal-title":"Lancet (london, England)"},{"key":"1088_CR22","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/s0140-6736(89)91793-5","volume":"2","author":"OS Morgan","year":"1989","unstructured":"Morgan OS, Rodgers-Johnson P, Mora C et al (1989) HTLV-1 and polymyositis in Jamaica. Lancet (london, England) 2:1184\u20131187. https:\/\/doi.org\/10.1016\/s0140-6736(89)91793-5","journal-title":"Lancet (london, England)"},{"key":"1088_CR23","doi-asserted-by":"crossref","unstructured":"Nagai M, Usuku K, Matsumoto W et al (1998) Analysis of HTLV-I proviral load in 202 HAM\/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM\/TSP. J Neurovirol 4:586\u201393.\u00a0http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10065900\u00a0(accessed 11 Sep 2014)","DOI":"10.3109\/13550289809114225"},{"key":"1088_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1136\/ard.56.3.167","volume":"56","author":"H Nakamura","year":"1997","unstructured":"Nakamura H, Eguchi K, Nakamura T et al (1997) High prevalence of Sj\u00f6gren\u2019s syndrome in patients with HTLV-I associated myelopathy. Ann Rheum Dis 56:167\u2013172. https:\/\/doi.org\/10.1136\/ard.56.3.167","journal-title":"Ann Rheum Dis"},{"key":"1088_CR25","doi-asserted-by":"publisher","unstructured":"Olavarria VN, Gomes ADN, Kruschewsky RDA et al (2012) Evolution of HTLV-1 proviral load in patients from Salvador, Brazil. Braz J Infect Dis 16:357\u201360. https:\/\/doi.org\/10.1016\/j.bjid.2012.06.022","DOI":"10.1016\/j.bjid.2012.06.022"},{"key":"1088_CR26","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/01.wnl.0000096011.92542.da","volume":"61","author":"JR Orland","year":"2003","unstructured":"Orland JR, Engstrom J, Fridey J et al (2003) Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study. Neurology 61:1588\u20131594. https:\/\/doi.org\/10.1212\/01.wnl.0000096011.92542.da","journal-title":"Neurology"},{"key":"1088_CR27","doi-asserted-by":"crossref","unstructured":"Osame M, Usuku K, Izumo S et al (1986) HTLV-I associated myelopathy, a new clinical entity. Lancet 1:1031\u20132. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/2871307","DOI":"10.1016\/S0140-6736(86)91298-5"},{"key":"1088_CR28","doi-asserted-by":"publisher","unstructured":"Rosadas C, Zetterberg H, Heslegrave A et al (2021) Neurofilament light in CSf and plasma is a marker of neuronal damage in HTLV-1-associated myelopathy and correlates with neuroinflammation. J Neurol Neuroimmunol neuroinflammation 8(6):e1090. https:\/\/doi.org\/10.1212\/NXI.0000000000001090","DOI":"10.1212\/NXI.0000000000001090"},{"key":"1088_CR29","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1099\/vir.0.80509-0","volume":"86","author":"AH Sabouri","year":"2005","unstructured":"Sabouri AH, Saito M, Usuku K et al (2005) Differences in viral and host genetic risk factors for development of human T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy\/tropical spastic paraparesis between Iranian and Japanese HTLV-1-infected individuals. J Gen Virol 86:773\u2013781. https:\/\/doi.org\/10.1099\/vir.0.80509-0","journal-title":"J Gen Virol"},{"key":"1088_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/cid\/civ229","volume":"61","author":"D Tanajura","year":"2015","unstructured":"Tanajura D, Castro N, Oliveira P et al (2015) Neurological manifestations in human T-cell lymphotropic virus type 1 (HTLV-1)-infected individuals without HTLV-1-associated myelopathy\/tropical spastic paraparesis: a longitudinal cohort study. Clin Infect Dis 61:49\u201356. https:\/\/doi.org\/10.1093\/cid\/civ229","journal-title":"Clin Infect Dis"},{"key":"1088_CR31","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/00042560-199909010-00012","volume":"22","author":"GP Taylor","year":"1999","unstructured":"Taylor GP, Tosswill JH, Matutes E et al (1999) Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 22:92\u2013100. https:\/\/doi.org\/10.1097\/00042560-199909010-00012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1088_CR32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/jmv.23711","volume":"86","author":"C Toledo-Cornell","year":"2014","unstructured":"Toledo-Cornell C, Santos S, Orge G et al (2014) Soluble IL-2 receptor and beta-2 microglobulin as possible serologic markers of neurologic disease in HTLV-1 infection. J Med Virol 86:315\u2013321. https:\/\/doi.org\/10.1002\/jmv.23711","journal-title":"J Med Virol"},{"key":"1088_CR33","first-page":"382","volume":"49","author":"World Health Organization","year":"1989","unstructured":"World Health Organization (1989) WHO diagnostic guidelines of HAM. Wkly Epidemiol Rec 49:382\u2013383","journal-title":"Wkly Epidemiol Rec"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-022-01088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-022-01088-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-022-01088-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T15:25:10Z","timestamp":1672241110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-022-01088-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,30]]},"references-count":33,"journal-issue":{"issue":"4-6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1088"],"URL":"https:\/\/doi.org\/10.1007\/s13365-022-01088-x","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,30]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Alector, Eisai, Denali, Roche Diagnostics, Wave, Samumed, Siemens Healthineers, Pinteon Therapeutics, Nervgen, AZTherapies, CogRx, and Red Abbey Labs, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure and Biogen, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. All other co-authors have no potential conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}